Clivatuzumab

• CAT Number: I041519
• CAS Number: 1622075-09-5
• Purity: ≥95%

Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers[1].
Clivatuzumab demonstrates high specificity for pancreatic ductal adenocarcinoma (PDAC) with little to no reactivity towards normal and benign, non-neoplastic, pancreatic tissues, although it does show limited reactivity (approximately 10% of all specimens examined) with adenocarcinomas originating in certain other organs (e.g., stomach, colon, lung)[1].

Reference

[1]. Gold DV, et al. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer. 2013 Nov 20;12(1):143.
 [Content Brief]